Serologic Response of 2 Versus 3 Doses and Intradermal Versus Intramuscular Administration of a Licensed Rabies Vaccine for Preexposure Prophylaxis. (6th December 2019)

• Record Type: Journal Article
• Authors: Endy, Timothy P; Keiser, Paul B; Wang, Dongliang; Jarman, Richard G; Cibula, Don; Fang, Hengsheng; Ware, Lisa; Abbott, Mark; Thomas, Stephen J; Polhemus, Mark E
• Is Part Of: Journal of infectious diseases. Volume 221:Number 9(2020)
• Page Start: 1494
• Page End: 1498
• Publication Date: 2019-12-06
• Subjects: rabies -- vaccine -- intradermal -- intramuscular -- immunogenicity; Communicable diseases -- Periodicals; Diseases -- Causes and theories of causation -- Periodicals; Medicine -- Periodicals; Communicable Diseases -- Periodicals; Electronic journals; 616.9
• DOI: 10.1093/infdis/jiz645
• Languages: English
• ISSNs: 0022-1899

Abstract

Abstract: Background: The World Health Organization recommends intradermal (ID) administration of rabies vaccine for preexposure prophylaxis. Methods: In a randomized trial in adults assigned to 1 of 6 treatment groups (ID vs intramuscular [IM], 2 vs 3 doses, and controls), rabies neutralizing antibody titers were measured to 1 year postvaccination. Results: ID vaccination produced acceptable antibody levels in all subjects (2- and 3-dose groups). At day 365, acceptable levels were 40% for IM and 50% for ID 2-dose schedule, and 70% for IM and 60% for ID 3-dose schedule. Conclusions: ID rabies vaccination induces acceptable antibody titers at a fraction of the dose. Clinical Trials Registration: NCT02374814.